FT-001

N/A

Report date: 2025/04/08 09:04:54

Base Information

Drug NameFT-001
Drug Alias NameFT-001FT-001(Frontera Therapeutics)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2 vector
Mechanisms of ActionRPE65 gene transference
TargetsRetinoid isomerohydrolase
Therapy Area/IndicationsRetinal DegenerationRetinal Dysplasia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesFangtuo Biotechnology (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCatalent Maryland IncFangtuo Biotechnology (Suzhou) Co LtdFrontera Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsRetinal DegenerationRetinal Dysplasia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A